Invention Grant
- Patent Title: Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes
-
Application No.: US15522958Application Date: 2015-10-28
-
Publication No.: US10011597B2Publication Date: 2018-07-03
- Inventor: Michael Rützler , Thomas Brimert , Klaus Dreisch , Johan Evenäs , Joakim Larsson
- Applicant: APOGLYX AB
- Applicant Address: SE Lund
- Assignee: APOGLYX AB
- Current Assignee: APOGLYX AB
- Current Assignee Address: SE Lund
- Agency: Polsinelli PC
- Agent Ron Galant
- Priority: SE1451289 20141029
- International Application: PCT/EP2015/075007 WO 20151028
- International Announcement: WO2016/066696 WO 20160506
- Main IPC: A61K31/4196
- IPC: A61K31/4196 ; A61K31/433 ; C07D417/12 ; C07D417/14 ; C07D403/12 ; C07D249/12 ; C07D285/135
Abstract:
Disclosed are compounds, pharmaceutical compositions and methods for modulating aquaporin 9.
Public/Granted literature
Information query
